Invokana (canagliflozin) was the first in a new class of drugs used to treat type 2 diabetes, called sodium-glucose cotransporter-2 (SGLT2) inhibitors, to receive approval by the U.S. Food and Drug Administration. (FDA). It was approved in March, 2013, and within a year of hitting the market the drug had been linked to at least 457 serious adverse … [Read more...]

Invokana (canagliflozin) is in a new class of drugs used to treat type 2 diabetes, called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Invokana’s use has been linked to a dangerous medical condition called ketoacidosis. Diabetic ketoacidosis often requires hospitalization and can be fatal. If you or someone you love has suffered ketoacidosis … [Read more...]

On June 22, 2015, Health Canada announced that it has initiated a safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors Invokana (canagliflozin) and Forxiga (dapagliflozin), and their risk of causing diabetic acidosis. SGLT2 inhibitors are a new class of drugs used to treat type 2 diabetes. Invokana was approved by the U.S. Food and … [Read more...]